Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A University of Oklahoma study found that children with juvenile idiopathic arthritis (JIA) on systemic anti-inflammatory medications progressed to myopia significantly more slowly than untreated peers. Kids not on anti-inflammatories became myopic before age 10, while treated kids stayed mostly farsighted until age 17. The findings suggest inflammation may play a key role in childhood eye elongation and myopia development.
A new study from the University of Oklahoma is turning heads in the eye care world: inflammation may be a key driver of myopia progression in children. Researchers compared eye exam records from 197 patients at the Dean McGee Eye Institute and found that kids with juvenile idiopathic arthritis (JIA) who were on systemic anti-inflammatory medications had significantly slower myopia progression than both untreated JIA patients and healthy controls.
The science behind it? Inflammatory mediators — the same cytokines involved in immune responses — appear to act on the sclera (the white outer layer of the eye), softening the tissue and allowing the eye to elongate under intraocular pressure, which is the hallmark of myopia. Untreated JIA patients showed the worst outcomes, becoming myopic before age 10 and continuing to worsen over time.
Key Takeaways:
Why it matters: With myopia rates rising globally and no consistently effective treatment to halt progression, this research opens a potentially new therapeutic avenue — anti-inflammatory therapy — that could reshape how clinicians approach childhood myopia management.
